Contact

Autifony Therapeutics Limited

Registration No. 07543962, Registered in England
Stevenage Bioscience Catalyst,
Gunnels Wood Road,
Stevenage,
Hertfordshire,
SG1 2FX,
UK
VAT Registration No. GB 325 4102 43

Contact us at: [email protected]

Autifony Srl Company

Registration No. 387419, Registered in Italy,
Registered Office:

Autifony Srl (Laboratories)
Istituto di Ricerca Pediatrica Citta’ della Speranza
Via Corso Stati Uniti, 4f
35127 Padova (PD) Italy

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Aug 26
Autifony Therapeutics regains rights to clinical stage Kv3 programme https://t.co/rBHjjR7aC0
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Aug 26
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more. Barbara's experience… https://t.co/u0VXnvXlGI
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
May 04
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
reply retweet favorite

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image